DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 194,600 shares, an increase of 28.4% from the November 30th total of 151,500 shares. Based on an average trading volume of 87,500 shares, the short-interest ratio is currently 2.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in DiaMedica Therapeutics in the third quarter worth $40,000. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at $87,000. Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth about $185,000. Finally, Geode Capital Management LLC increased its stake in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares in the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Stock Down 1.3 %

NASDAQ:DMAC opened at $5.34 on Tuesday. The firm’s fifty day simple moving average is $4.80 and its 200 day simple moving average is $4.04. The stock has a market cap of $228.34 million, a P/E ratio of -9.54 and a beta of 1.51. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.41.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.